Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680689 | 0.88 | PTK2 (0.73) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL6611048 | 0.78 | PTK2 (0.55) | PTK2MAPK8MAPK10IKBKBJAK2 | |
| SCHEMBL29064722 | 0.76 | MAPK8 (0.70) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL28676789 | 0.76 | PTK2 (0.47) | PTK2MAPK8MAPK10 | |
| SCHEMBL5550829 | 0.76 | PTPN2 (0.68) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL11946878 | 0.76 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL13270043 | 0.76 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL23323409 | 0.75 | PTK2 (0.69) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL5092793 | 0.75 | PTK2 (1.00) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL29064716 | 0.75 | MAPK8 (0.53) | PTK2MAPK8MAPK10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-12-17 | — | — | US | claimed |
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING (US) | 2014-06-12 | — | — | US | claimed |
| EP-2403497-A1 | COMPOUNDS, COMPOSITIONS AND USE FOR ANTICANCER THERAPY | Yu, Ming (CN) | 2012-01-11 | — | — | EP | claimed |
| US-20110142815-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | YU MING | 2011-06-16 | — | — | US | claimed |
| CN-101842095-A | Formulations, methods and targets for tumor therapy | MING YU | 2010-09-22 | — | — | CN | claimed |
| WO-2010099731-A1 | COMPOUNDS, COMPOSITIONS AND USE FOR ANTICANCER THERAPY | YU MING (CN) | 2010-09-10 | — | — | WO | claimed |
| EP-2178531-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | Yu, Ming (US) | 2010-04-28 | — | — | EP | claimed |
| WO-2009006555-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | YU, MING (US) | 2009-01-08 | — | — | WO | claimed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | disclosed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | disclosed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2010083240-A2 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | MIDCAP FINANCIAL TRUST | 2010-07-15 | — | — | US | disclosed |
| EP-2178531-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | Yu, Ming (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009006555-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | YU, MING (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179165-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS USING 2,4-PYRIMIDINEDIAMINE COMPOUNDS | IL2, IL17A, IL23R | PTK2 3635/4885MAPK8 3483/4885MAPK10 3356/4885 |
| US-20100179164-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS | IL2, IL1B, IL1A | PTK2 4196/4885MAPK8 2431/4885MAPK10 464/4885 |
| US-20200390825-A1 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | PKD1, PKD2, VHL | PTK2 1444/4885MAPK8 4108/4885MAPK10 3458/4885 |
| US-20140163088-A1 | COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY | DDIT3, MCL1, BAX | PTK2 315/4885MAPK8 154/4885MAPK10 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.